© PR Newswire
27.01.2026
LNAI
LISTED
NASDAQ
Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons
News Preview
Transformer-based biosecurity layer embeds directly into foundation models, using Lunai's proprietary toxicology and in-vivo datasets to detect and prevent creation of previously unknown threat agents in real time.SACRAMENTO, Calif., Jan. 27, 2026 /PRNewswire/ -- As global attention intensifies around the dual-use risks of advanced artificial inte...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
NNOX
LISTED
NASDAQ
AI Medical Imaging Revolution: Software-Native Tech Disrupts $45B Market
News Preview
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, Jan. 27, 2026 /CNW/ -- USANewsGroup.com News Commentary – The global medical imaging market hit a massive $45.5 billion in 2026[1], marking a total structural shift toward AI-native precision as advanced cancer therapies demand more intense heart monitoring than ever before[2]. Hospita...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
NNOX
LISTED
NASDAQ
AI Medical Imaging Revolution: Software-Native Tech Disrupts $45B Market
News Preview
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, Jan. 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The global medical imaging market hit a massive $45.5 billion in 2026[1], marking a total structural shift toward AI-native precision as advanced cancer therapies demand more intense heart monitoring than ever before[2]....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© ACCESS Newswire
27.01.2026
AYTU
LISTED
NASDAQ
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
News Preview
DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its seco...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Newsfile
27.01.2026
NURL
LISTED
CSE
Neural's Portfolio Company Hanf.com Announces Sales Start of Ritual Herbs Nicotine and Tobacco Free Products
News Preview
Toronto, Ontario--(Newsfile Corp. - January 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("C...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
BDX
LISTED
NYSE
BD to Announce Financial Results for its First Quarter of Fiscal 2026
News Preview
FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Monday, February 9, 2026 to discuss the Company's financial results for its first quarter of fiscal year 2026, which ended on ...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
BDX
LISTED
NYSE
Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business
News Preview
Waters Corporation's Q4 2025 Financial Results Conference Call will now be held on Monday, February 9th, 2026 at 8:30am ET in conjunction with the expected close of the transactionMILFORD, Mass., Jan. 27, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) (the "Company" or "Waters") today announced that, at the Company's Special Meeting of Shareh...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
BDX
LISTED
NYSE
Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business
News Preview
Waters Corporation's Q4 2025 Financial Results Conference Call will now be held on Monday, February 9th, 2026 at 8:30am ET in conjunction with the expected close of the transactionMILFORD, Mass., Jan. 27, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) (the "Company" or "Waters") today announced that, at the Company's Special Meeting of Shareh...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
BDX
LISTED
NYSE
BD Announces Record Date for the Spin-Off of its Biosciences & Diagnostic Solutions Business
News Preview
Distribution date and closing date for spin-off and merger with Waters Corporation set for February 9, 2026FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) ("BD" or the "Company") today announced that the Company's Board of Directors has set the close of business on February 5, 2026, as the record...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
VREX
LISTED
NASDAQ
Varex Schedules First Quarter Fiscal Year 2026 Earnings Release and Conference Call
News Preview
Varex Imaging Corporation (Nasdaq: VREX) today announced that it will report unaudited financial results for the first quarter of fiscal year 2026, following the close of regular trading on Tuesday, February 10, 2026. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day.
This call will be webcast live...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
3696
LISTED
HKSE
Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies
News Preview
CAMBRIDGE, Mass., Jan. 27, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center, today announced a strategic partnership on innova...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
6446
LISTED
TAI
PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for Treatment of Essential Thrombocythemia (ET)
News Preview
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the U.S. NCCN Clinical Practice Guidelines in Oncology have been updated t...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
27.01.2026
ANEB
LISTED
NASDAQ
Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer
News Preview
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced the preliminary results of its voluntary self-tender offer to purchase 300,000 shares of its common stock, par value $0.001 per...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
ANIX
LISTED
NASDAQ
Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology
News Preview
Notice of Allowance marks first Mexican patent to be issued on Anixa Breast Cancer VaccineExpands global intellectual property coverage in markets with greater late-stage breast cancer diagnoses and higher triple-negative breast cancer incidence ratesSAN JOSE, Calif., Jan. 27, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company")...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
DXCM
LISTED
NASDAQ
Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time.
News Preview
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2025 financial results after market close on Thursday, February 12, 2026. Management will hold a conference call to review the company's fourth quarter and fiscal year 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The con...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
TEM
LISTED
NASDAQ
Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its algorithmic test, Immune Profile Score (IPS), more accurately predicts outcomes for patients receiving immune checkpoint inhibitors (ICIs) than conventional biomarkers, includ...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
INMB
LISTED
NASDAQ
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
News Preview
Boca Raton, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO:...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC
LEI: 5493003YBCY4W1IMJU04
NET ASSET VALUE
The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
SVRA
LISTED
NASDAQ
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the amendment of its loan and security agreement with Hercules Capital, Inc. (NYSE:HTGC), strengthening its balance sheet and liquidity.
Under the terms of the amended loan agreement, up to an additional $75...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
DCTH
LISTED
NASDAQ
Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference at the Cliff Lodge in Snowbird, Utah.
About Delcath System...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
KZIA
LISTED
NASDAQ
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
News Preview
SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC).
To date, three patients with metastatic TNBC treat...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
VNRX
LISTED
XASE
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
News Preview
Nu.Q® Biomarker Paper Available on MedRXIV HENDERSON, Nev., Jan. 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the release of a new clinical study demonstrating the use of its Nu.Q® NETs assay in patient management for a chronic disease, Hidradenitis Suppurativa (HS)...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
BNBX
LISTED
NASDAQ
BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th
News Preview
BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced that Chief Investment Officer Patrick Horsman, CFA and Chairman of the Board Joshua Kruger will present live at the Digital Asset Virtual Investor Conference hosted by Virtual InvestorConferences.com, on January 27th, 2026 at 1:00PM EST.
DATE: January 27th, 2026
TIME: 1:00P...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
ATRC
LISTED
NASDAQ
AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026.
AtriCure will host an audio...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
JNJ
LISTED
NYSE
Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile
News Preview
Johnson & Johnson, with support from the Johnson & Johnson (J&J) Foundation, announced that it has donated $100 million of MedTech products since 2020 to help more people around the world access the specialized care they need to live, see and smile. The Company has also planned to contribute an additional $20 million toward programs an...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
AHCO
LISTED
NASDAQ
AdaptHealth Corp. Announces Upgraded Moody’s Ratings
News Preview
AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that Moody’s Ratings (Moody’s) has recently upgraded the ratings of AdaptHealth, LLC, including the Corporate Fami...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
INCY
LISTED
NASDAQ
Incyte to Report Fourth Quarter and Year-End 2025 Financial Results
News Preview
Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 10, 2026.
The schedule for the press release and conference call/webcast is as follows:
Q4 & YE 2025 Press Release: February 10, 2026 at 7:00 a.m. ET
Q4 &...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.01.2026
TRNR
LISTED
NASDAQ
TRNR Publishes Shareholder Letter and Investor Presentation with 2026 Revenue Guidance of More Than $20M
News Preview
Company Comments on Delivering Value from Sportstech Enforcement and Highlights Strengthened Business Operations Entering 20262026 Revenue Guidance of More Than $20M Represents Nearly 100% 2-Year CAGR AUSTIN, TX / ACCESS Newswire / January 27, 2026 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or the "Company"), maker of inn...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
DCGO
LISTED
NASDAQ
DocGo’s SteadyMD Announces Immediate Expansion of Clinical Workforce to Meet Rising Demand for Branded GLP-1 Weight Loss Care
News Preview
DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health and medical transportation services, today announced that its virtual care division, SteadyMD, is undertaking an immediate expansion of its clinical workforce, with plans to increase clinical staff by up to 50% over the coming weeks. The hi...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
LQDA
LISTED
NASDAQ
Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress
News Preview
MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today the company will present three posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress to be held Janua...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
QNRX
LISTED
XANS
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome
News Preview
Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
BAYN
LISTED
XETR
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
News Preview
Bayer today announced that the main results from its global, landmark Phase III study OCEANIC-STROKE of asundexian in secondary stroke prevention, will be presented during two late-breaking sessions at the upcoming American Stroke Association’s International Stroke Conference (ISC) 2026. The conference will be held February 4-6 in New Orleans, Lou...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA i...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
ICLR
LISTED
NASDAQ
ICON’s Accellacare Site Network Expands Oncology Research Capabilities With New Cancer Institute Partnership
News Preview
ICON plc (NASDAQ: ICLR) today announced a significant expansion of oncology research capabilities within its Accellacare Site Network through the opening of the Brian Moran Cancer Institute at Duly Health and Care in Illinois.
The new institute strengthens Accellacare’s ability to support oncology clinical trials and broaden access to innovative...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
NEO
LISTED
NASDAQ
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Tuesday, February 17, 2026. Company management will host a webcast and conference call at...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
VEEV
LISTED
NYSE
Industry Research Finds Establishing a Foundation for AI is Top Priority for CPG Enterprises
News Preview
82% of organizations moving to unified platforms for standardized data and processes, AI readinessBARCELONA, Spain, Jan. 27, 2026 /PRNewswire/ -- A new industry report shows that building an AI-ready infrastructure is a top priority for consumer product goods (CPG) companies. The State of AI in Consumer Goods Report found most (82%) respondents ar...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
VEEV
LISTED
NYSE
Industry Research Finds Establishing a Foundation for AI is Top Priority for CPG Enterprises
News Preview
82% of organizations moving to unified platforms for standardized data and processes, AI readinessPLEASANTON, Calif., Jan. 27, 2026 /PRNewswire/ -- A new industry report shows that building an AI-ready infrastructure is a top priority for consumer product goods (CPG) companies. The State of AI in Consumer Goods Report found most (82%) respondents...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
AMRX
LISTED
NASDAQ
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
News Preview
BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
LSTA
LISTED
NASDAQ
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
News Preview
Lisata regains full development rights to certepetide in the Greater China Region Lisata regains full development rights to certepetide in the Greater China Region...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
TEVA
LISTED
TLV
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
News Preview
PARSIPPANY, N.J., and TEL AVIV, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a partnership with actor, comedian and advocate, Will Forte, to increase awareness of Huntington’s disease (HD). HD, a rare, progressive neurological disorde...
Themefolio
Profiler
Peergroup
© Newsfile
27.01.2026
KPRX
LISTED
NASDAQ
Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board
News Preview
Encinitas, California--(Newsfile Corp. - January 27, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed leading retina specialist, Dr. Taiji Sakamoto, an expert in the treatment of retinal disease, to its Scientific Advisory Board. As an advisor, Dr. Sakamoto, currently the Chair of Ophthalmology at Kagoshima University, will contribute cli...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
HCA
LISTED
NYSE
HCA Healthcare Reports Fourth Quarter 2025 Results and Provides 2026 Guidance
News Preview
HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the fourth quarter ended December 31, 2025.
Key fourth quarter metrics (all percentage changes compare 4Q 2025 to 4Q 2024 unless otherwise noted):
Revenues increased 6.7 percent to $19.513 billion
Net income attributable to HCA Healthcare, Inc. increased 3...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
BCT
LISTED
TSX
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
News Preview
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces new positive Phase 2 survival data highlighting multip...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
CYTK
LISTED
NASDAQ
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
News Preview
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
TGTX
LISTED
NASDAQ
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
News Preview
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 5 – 7, 2026 in San Diego, Californ...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
LXEO
LISTED
NASDAQ
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics
News Preview
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Partnership for Cardiac RNA Therapies...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
CGTX
LISTED
NASDAQ
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
News Preview
PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a Type C meeting with the U.S. Food and Drug Administration (FDA) on January 21, 2026. The objective of this meeting was to review pl...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
CRDF
LISTED
NASDAQ
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
News Preview
- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS-mutated mCRC –...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
AXSM
LISTED
NASDAQ
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
News Preview
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year 2025 on Monday, February 23, 2026, before the opening of the U.S....
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
UNH
LISTED
NYSE
UnitedHealth Group Reports 2025 Results and Issues 2026 Outlook
News Preview
UnitedHealth Group (NYSE: UNH) today reported full year and fourth quarter 2025 results and issued its 2026 outlook.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126830491/en/
“We confronted challenges directly and finished 2025 as a much stronger company, giving us the momentum t...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
2096
LISTED
XETRA
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
News Preview
Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset.Boehringer receives global rights to the asset, excluding great...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
2096
LISTED
XETRA
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
News Preview
Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset.Boehringer receives global rights to the asset, excluding great...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
GLSI
LISTED
NASDAQ
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy
News Preview
STAFFORD, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided additional update...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
ZYME
LISTED
NYSE
Zymeworks Announces Participation in Upcoming Investor Conferences
News Preview
VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.01.2026
JUNS
LISTED
NASDAQ
Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference
News Preview
JUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform for neuroinflammation and healthy aging, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.01.2026
PSYG
LISTED
XCQ
Psyence Group's RTO Target, GoldCoast Resource Corp., Granted Offshore Reconnaissance License for Gold Exploration on Ghana's Shallow Continental Shelf
News Preview
TORONTO, ON / ACCESS Newswire / January 27, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") announces that its proposed reverse takeover target, GoldCoast Resource Corp. ("GoldCoast"), has been granted a series of ten contiguous offshore reconnaissance licenses by the Minerals Commission of Ghana (the...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.01.2026
POROF
LISTED
OTC
Cellev8 Receives Official Name Change by FINRA
News Preview
Preferred Commerce takes next steps with FINRA for Corporate Name Change to Cellev8 Nutrition Inc. (CELV) WELLINGTON, FL / ACCESS Newswire / January 27, 2026 / Preferred Commerce announced today that it has received final approval from the Financial Industry Regulatory Authority (FINRA) to change its corporate name to Cellev8 Nutrition Inc. (CELV),...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.01.2026
CNSP
LISTED
NASDAQ
CNS Pharmaceuticals Issues Letter to Shareholders
News Preview
Newly Appointed President & Chief Executive Officer, Rami Levin, Discusses Plans for a New Era at CNS PharmaceuticalsStrategic Focus, Pipeline Optimization and Formalizing Roadmap for Near and Long-Term Value Creation HOUSTON, TX / ACCESS Newswire / January 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.01.2026
OSRH
LISTED
NASDAQ
OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries
News Preview
BELLEVUE, WA / ACCESS Newswire / January 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced the official closing of its acquisition of Woori IO, the reaffirmation of long-term equity alignment by Woori IO's historical shareholders, and the initiation of a strategic review regarding a potential combination of its medical device subsidiaries...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.01.2026
ASBP
LISTED
NASDAQ
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks
News Preview
New sublingual delivery system designed to enhance bioavailability and avoid gastric side effects many patients experience with clopidogrel.Clopidogrel, currently sold under the brand name Plavix®, was the 41st most commonly prescribed medication in the United States, with more than 15.2 million combined branded and generic prescriptions in 20...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
